FindTrial
Sign In

Correlation of Immune Checkpoint Inhibitor-Induced Endocrine Immune-Related Adverse Events with Prognosis in Malignancies: A Retrospective Cohort Study

Correlation of Immune Checkpoint Inhibitor-Induced Endocrine Immune-Related Adverse Events with Prognosis in Malignancies: A Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102707
Enrollment
Unknown
Registered
2025-05-19
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Occurrence of immune related adverse events group:None
No immune related adverse events occurred group:None

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age>= 18 years old; 2.Diagnosed with malignant tumors (non-small cell lung cancer, hepatocellular carcinoma, melanoma, renal cell carcinoma, cervical cancer, endometrial cancer, ovarian cancer, etc.); 3.Previously/currently undergoing immune checkpoint inhibitor therapy;

Exclusion criteria

Exclusion criteria: 1.Immune checkpoint inhibitor treatment<2 courses; 2.Endocrine related diseases occurred before treatment with immune checkpoint inhibitors; 3.Missing information;

Design outcomes

Primary

MeasureTime frame
3-year progression free survival rate;3-year overall survival rate;—

Countries

China

Contacts

Public ContactXiaoming Chen, Zhennan Wang

Affiliated Hospital of Guangdong Medical University

zhennan_wang163@163.com+86 13828296230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026